Home › Compare › SHNUF vs ABBV
SHNUF yields 10.00% · ABBV yields 3.06%● Live data
📍 SHNUF pulled ahead of the other in Year 1
Combined, SHNUF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SHNUF + ABBV for your $10,000?
Intouch Holdings Public Company Limited, through its subsidiaries, engages in the satellite, Internet, telecommunications, and media and advertising businesses. It operates through Local Wireless Telecommunications, Satellite and International Businesses, and Other Businesses segments. The company offers transponder rental and related services for domestic and international communications; broadband content services; satellite uplink-downlink, broadcasting television and telecommunication services; Internet data center, Internet, and telecommunication services; advertising, insurance broker, and other related services; and sale and service related to media, telephone network, mobile content, and engineering development services on communication technology and electronics. It also sells user terminals of IPSTAR and direct television equipment; and distributes internet equipment. In addition, the company offers local mobile telecommunication services; provides computer program and related services, as well as information technology and home shopping services; and trades in and rents telecommunications equipment and accessories. It has operations in Thailand, Australia, India, Japan, Myanmar, Malaysia, and internationally. The company was formerly known as Shin Corporation Public Company Limited and changed its name to Intouch Holdings Public Company Limited in March 2014. Intouch Holdings Public Company Limited was founded in 1983 and is based in Bangkok, Thailand. As of December 31, 2021, Intouch Holdings Public Company Limited operates as a subsidiary of Gulf Energy Development Public Company Limited.
Full SHNUF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.